VCAN在肝细胞癌中的表达及其与预后的关系

Expression of VCAN in Hepatocellular Carcinoma and Its Relationship with Prognosis

摘要: 目的：评估硫酸软骨素蛋白聚糖(Versican, VCAN)在肝细胞癌患者中的表达，及其与肝细胞癌患者临床病理特征和预后的关系。方法：2022年2月通过TCGA数据库下载374例肝细胞癌患者肿瘤组织和50例癌旁组织的VCANmRNA表达数据以及患者临床病理信息。分析肝细胞癌组织中VCANmRNA表达与癌旁组织有无差异，进一步分析VCANmRNA与患者预后及临床病理特征的关系。结果：374例胃癌组织中VCANmRNA的表达量为0.74 (2.20, 2.34)，50例癌旁组织中VCANmRNA的表达量为0.39 (0.23, 0.58)，差异有统计学意义(P < 0.05)。VCANmRNA高表达组中位生存时间为3.76年，低表达组中位生存时间为5.07年，高表达组5年生存率为41.1%，低表达组5年生存率为56.1%。差异有统计学意义(P < 0.05)。单因素Cox回归结果显示，VCANmRNA表达与患者性别(P < 0.01)、TNM分期(P = 0.048)及T分期(P = 0.037)有显著相关性(P < 0.05)。多因素Cox回归分析显示，患者的TNM分期(P < 0.001)、远处转移(P = 0.003)、VCANmRNA表达量(P = 0.031)是肝细胞癌患者预后的独立危险因素，VCANmRNA高表达较低表达死亡风险增加1.12倍。结论：VCAN可能是促进肝细胞癌细胞增殖的一个关键基因，可能是肝细胞癌潜在的预后生物标志物。

Abstract: Objective: To evaluate the expression of Versican (VCAN) in patients with hepatocellular carcinoma and its relationship with clinicopathological features and prognosis. Methods: VCANmRNA expression data and clinicopathological information of 374 hepatocellular carcinoma patients from tumor tissues and 50 paracancer tissues were downloaded from TCGA database in February 2022. The expression of VCANmRNA in hepatocellular carcinoma tissues and adjacent tissues was analyzed, and the relationship between VCANmRNA and prognosis and clinicopathological features of patients was further analyzed. Results: The expression level of VCANmRNA in 374 gastric cancer tissues was 0.74 (2.20, 2.34), and that in 50 adjacent tissues was 0.39 (0.23, 0.58), the difference was statistically significant (P < 0.05). The median survival time was 3.76 years in the high expression group and 5.07 years in the low expression group. The 5-year survival rate was 41.1% in the high expression group and 56.1% in the low expression group. The difference was statistically significant (P < 0.05). Univariate Cox regression showed that VCANmRNA expression was significantly correlated with gender (P < 0.01), TNM stage (P = 0.048) and T stage (P = 0.037) (P < 0.05). Multivariate Cox regression analysis showed that TNM stage (P < 0.001), distant metastasis (P = 0.003) and VCANmRNA expression (P = 0.031) were independent risk factors for prognosis of patients with HCC, and the risk of death increased by 1.12 times compared with low expression of VCANmRNA. Conclusion: VCAN may be a key gene promoting the proliferation of hepatocellular carcinoma and a potential prognostic biomarker of hepatocellular carcinoma.